Home LiteratureArticle Details

PMID: 17428949 Published · ppublish English Comparative Study Journal Article Multicenter Study Randomized Controlled Trial

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.

Clinical and vaccine immunology : CVI ·Vol. 14 ·No. 6 ·2007-06-00 ·Pages 792-5

Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Esser MT, Vuocolo SC, Nelson M, Railkar R, Sattler C, Barr E, 012 Study Investigators

Abstract

The incorporation of multiple antigens into a single human papillomavirus (HPV) vaccine may induce immune interference. To evaluate whether interference occurs when HPV type 16 (HPV16) virus-like particles are combined in a multivalent vaccine, we conducted a study to evaluate anti-HPV16 responses among subjects receiving three-dose regimens of either a monovalent HPV16 vaccine or a quadrivalent HPV (types 6, 11, 16, and 18) vaccine.

MeSH Terms

Adolescent Adult Antibodies, Viral/biosynthesis Antibody Formation/immunology Double-Blind Method Female Human papillomavirus 16/immunology Humans Papillomavirus Infections/prevention & control Papillomavirus Vaccines/administration & dosage,classification,immunology

Chemicals

Antibodies, Viral Papillomavirus Vaccines

Authors & Affiliations

17 authors, click to expand affiliations / ORCID

Garland Suzanne M

Microbiology and Infectious Diseases Department, Royal Women's Hospital, Carlton, University of Melbourne, Melbourne, Victoria, Australia.

Steben Marc

Hernandez-Avila Mauricio

Koutsky Laura A

Wheeler Cosette M

Perez Gonzalo

Harper Diane M

Leodolter Sepp

Tang Grace W K

Ferris Daron G

Esser Mark T

Vuocolo Scott C

Nelson Micki

Railkar Radha

Sattler Carlos

Barr Eliav

012 Study Investigators

References (10)

10 references, click to expand

Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
N Engl J Med. 2002 Nov 21;347(21):1652-61 PMID: 12444179
Epidemiologic classification of human papillomavirus types associated with cervical cancer.
N Engl J Med. 2003 Feb 6;348(6):518-27 PMID: 12571259
Comparative analysis of two rates.
Stat Med. 1985 Apr-Jun;4(2):213-26 PMID: 4023479
Combination vaccines consisting of acellular pertussis vaccines.
Pediatr Infect Dis J. 1997 Apr;16(4 Suppl):S97-102 PMID: 9109164
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
N Engl J Med. 2007 May 10;356(19):1928-43 PMID: 17494926
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
J Pathol. 1999 Sep;189(1):12-9 PMID: 10451482
Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid.
Pediatr Infect Dis J. 2005 Jan;24(1):85-6 PMID: 15665717
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
Lancet Oncol. 2005 May;6(5):271-8 PMID: 15863374
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.
Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69 PMID: 16085914
Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel.
Sex Transm Dis. 1999 Apr;26(4 Suppl):S2-7 PMID: 10227693

Article Info

Journal

Clinical and vaccine immunology : CVI

Abbr.

Clin Vaccine Immunol

ISSN

1556-6811

DOI

10.1128/CVI.00478-06

Published

2007-06-00

Epub

2007-00-11

Pages

792-5

Language

English

Region

United States

NLM ID

101252125

PMCID

PMC1951095

Subset

External Links

PubMed source DOI: 10.1128/CVI.00478-06 PMC Full Text View journal details

Analysis Services

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.

Contact

WeChat Official Account